Research on Inflammation, Stress, and Energy (RISE), 1R01-CA160427
Fatigue is one of the most common and distressing side effects of cancer treatment and may persist for months or years after treatment completion. This study, funded by the National Cancer Institute, was designed to identify predictors and mechanisms for cancer-related fatigue, with a focus on inflammation as a key driver of fatigue symptoms. We enrolled 270 women with early stage breast cancer and followed them from diagnosis into survivorship with intensive biobehavioral assessments. We are now conducting analyses of this rich data set, with initial work focusing on biobehavioral predictors of pre-treatment fatigue and using growth mixture modeling to identify distinct trajectories of fatigue over time. We are also looking at early life stress and depression in RISE participants. Selected references from RISE are listed below.
RISE 2.0, 1R01-CA237535
This study, funded by the National Cancer Institute, is designed to examine accelerated aging in women with breast cancer. Cancer treatments lead to a number of age-related symptoms and conditions, including problems with cognition (“chemo brain”), energy, and physical function. We hypothesize that biological aging may be a driver of these effects, and will test this hypothesis using biological samples collected from RISE study participants. In addition, we will examine protective factors that may buffer against treatment effects on biological and physical aging processes. In a preliminary study, we found that cancer treatment was associated with accelerated epigenetic aging (see reference below), and that maintaining healthy sleep protected against this effect.
Pathways to Wellness (PTW), 1R01-CA200977
Cancer is stressful for everyone, but younger women are at particular risk for depression, stress, and other negative side effects of breast cancer and its treatment. The goal of the PTW study, funded by the National Cancer Institute, is to evaluate two specialized interventions for younger breast cancer survivors – mindfulness meditation and survivorship education. The primary outcome is depression, and we are also evaluating intervention effects on associated behavioral symptoms (fatigue, sleep) and inflammation. We recently completed data collection for this multi-site, randomized controlled trial and are beginning data analysis. See below for references to publications from our earlier, pilot trial of mindfulness for younger breast cancer survivors